Üçlü negati̇f meme kanserleri̇ni̇ndemografi̇k kli̇ni̇k ve patoloji̇kkarakteri̇sti̇kleri̇

Introduction While the histopathological classification is the main item in managing the breast cancer that is the most common cancer of women, immunohistochemical classification is getting important in nowadays. Triple negative breast cancer, a type of this classification in which receptors for estrogen, progesterone and c-erbB2 are negative, seem to have different clinical course, recurrence pattern. In our study we evaluated retrospectively clinical demographic and pathlogical characteristics of triple negative breast cancers, and investigated the association of these characteristics with overall and proression free survival of these patients. Patients and Methods Fifty-nine patients with triple negative breast cancer histology followed in Medical Oncology Unites in Adana and Ankara Hospitals of Baskent University between 1997 and 2009 were enrolled into the study. These pateients were mostly initially treated with adjuvant and neoadjuvant chemotherapy. The median age of patients was 49. Median followup duration was 27 months. (Min:0.27, max:132 months). Two patients were dead during the follow-up. Invasive ductal carcinoma pathology was reported in 38 patients, invasive lobuler carsinom in 3 patients, invasive meduller carsinom in 5 patients. Adjuvant chemotherapy was given to 43 patients. Relapses were seen in 15 patients. The most common metastatic site was lung. Patients having high grade tumor, 3 + lymph node or more, positive family history, younger age have statistically higher chance of relapse during followup. Discussion In accordance with the literature, our triple negative breast cancer patients showed more agressive porogression. Although median followup is short, one fourth of the patients having recurrence support nature of the triple negative breast cancer patients. In our study, triple negative patients had younger age at diagnosis, high grade tumors and more tendency to metastasize visceral organs. Currently standart tratment of triple negative breast cancer is chemotherapy. Anthracyclines and taxnanes are effective chemotherapeutic agents. Cisplatin resulting in DNA double strand breaks and PARP-1 inhibitors are promising agents in the mangement of triple negative breast cancer.